Centaurus Financial’s TG Therapeutics TGTX Stock Holding History

Centaurus Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,065	Closed	-$834K	–	979
2021 Q3	$834K	Buy	25,065 +65	+0.3%	+$2.01K	0.07%	306
2021 Q2	$970K	Sell	25,000 -1,000	-4%	-$39.3K	0.08%	278
2021 Q1	$1.25M	Hold	26,000	–	–	0.12%	202
2020 Q4	$1.35M	Hold	26,000	–	–	0.14%	176
2020 Q3	$696K	Buy	26,000 +6,000	+30%	+$138K	0.1%	228
2020 Q2	$390K	Buy	20,000 +5,000	+33%	+$80.5K	0.06%	303
2020 Q1	$148K	Buy	15,000 +5,000	+50%	+$63.2K	0.03%	408
2019 Q4	$111K	Hold	10,000	–	–	0.02%	591
2019 Q3	$56K	Hold	10,000	–	–	0.01%	440
2019 Q2	$87K	Buy	10,000 +9,920	+12,400%	+$75K	0.01%	584
2019 Q1	$10K	Buy	+80	New	+$432	0.06%	261

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Centaurus Financial's TGTX Position: Q4 2021 in Review

Centaurus Financial sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 25,065 shares — an estimated $834K sold.

Centaurus Financial first reported a position in TGTX in Q1 2019 and held it in 11 quarters. The position peaked at $1.35M in Q4 2020. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

Centaurus Financial reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
Centaurus Financial sold 25,065 TG Therapeutics shares in Q4 2021, an estimated $834K.
Centaurus Financial first reported a position in TG Therapeutics in Q1 2019 and held it in 11 quarters.
Centaurus Financial's TG Therapeutics position peaked at $1.35M in Q4 2020.
194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on Centaurus Financial's 13F filing for Q4 2021, filed 1 Feb 2022.